Figure 3.

The effect of VP-16 on replication factories is dose dependent. Exponentially growing HeLa cells were treated for 3 h with different concentrations of VP-16 and analyzed in indirect immunofluorescence with 2B1 mAb and with FITC-conjugated goat anti-mouse IgG secondary antibody. Confocal laser images were taken. a to f correspond, respectively, to cells treated with 0, 2, 10, 20, 50 and 100 μM VP-16. The arrows point to cells in which hLigI has a typical mid-S-phase pattern. Note the progressive disassembly of the replication factories.